L&K Biomed엘앤케이바이오
156100 · KOSDAQ · ₩156100 · 엘앤케이바이오
₩6,270▼ ₩910 (12.67%)End-of-day · Oct 29, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩39B | ₩36B | ₩30B | ₩20B | ₩15B |
| Cost of sales | ₩6.8B | ₩5.8B | ₩4.1B | ₩4.9B | ₩7.9B |
| Gross profit | ₩32B | ₩30B | ₩26B | ₩15B | ₩7.5B |
| Operating income | ₩715M | ₩3.1B | ₩2B | −₩13B | −₩15B |
| Net income | −₩17B | ₩9.2B | −₩5.2B | −₩16B | −₩14B |
| Net income to shareholders | −₩16B | ₩9.7B | −₩1.9B | −₩14B | −₩9.7B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩83B | ₩83B | ₩63B | ₩53B | ₩59B |
| Current assets | ₩61B | ₩64B | ₩44B | ₩36B | ₩38B |
| Cash and equivalents | ₩3.2B | ₩3.8B | ₩5B | ₩7.4B | ₩16B |
| Total liabilities | ₩45B | ₩47B | ₩32B | ₩42B | ₩34B |
| Current liabilities | ₩38B | ₩39B | ₩23B | ₩38B | ₩13B |
| Borrowings | ₩16B | ₩22B | ₩11B | ₩23B | ₩20B |
| Total equity | ₩39B | ₩36B | ₩31B | ₩11B | ₩25B |
| Shareholders' equity | ₩45B | ₩42B | ₩35B | ₩12B | ₩24B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩14B | −₩7.4B | −₩1.4B | −₩6.9B | −₩11B |
| Capital spending | ₩3B | ₩585M | ₩2B | −₩197M | −₩99M |
| Free cash flow | −₩17B | −₩8B | −₩3.4B | −₩7.1B | −₩11B |
Consolidated where available. Amounts in won.
Also known as: L&K Biomed / 엘앤케이바이오 / 156100 / KRX:156100
Source: KRX statistical information